OPA12 LEVELS OF SQUAMOUS CELL CARCINOMA ANTIGEN AND INTERLEUKIN-6 IN NON-SMALL CELL LUNG CANCER PATIENTS BEFORE CHEMOTHERAPY

Lydia Arieta1, Noni N. Soeroso2, Setia Putra Tarigan2
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of North Sumatera, Medan, Indonesia1
Division of Pulmonary Oncology, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of North Sumatera, Medan, Indonesia 2

Introduction:

Squamous Cell Carcinoma Antigen (SCCA) as a tumor marker and Interleukin-6 (IL‐6) pro-inflammatory cytokines has been widely used for monitoring Non-Small Cell Lung Cancer (NSCLC). This concentration also known to be higher in Non-Small Cell Lung Cancer (NSCLC).

Objectives:

To determine if Squamous Cell Carcinoma Antigen levels as a specific tumor maker and Interleukin-6 (IL-6) as a pro-inflammatory cytokine increased in patients Non-Small Cell Lung Cancer (NSCLC).

Methodology:

This research used descriptive study among Non-Small Cell Lung Cancer (NSCLC) patients. Blood sampling was used with serum. ELISA platform (semi-quantitative) was used to rate Squamous Cell Carcinoma Antigen and IL-6 serum. The data of serum levels collected and statistically analyzed.

Results:

Results of 20 samples Non-Small Cell Lung Cancer (NSCLC), we found 20 males (100%), active smokers (80%). From histology type, Adenocarcinoma 12 cases (60%). The most of subjects were in stage IVA (70%). The Squamous Cell Carcinoma Antigen levels of NSCLC patients showed that as many as 20 samples (100%) were within normal limits and did not show an increased. Levels of IL-6 increased as many as 15 samples (75%), and IL-6 levels were still within the normal range sample (25%).

Conclusions:

Tumor marker are not meant to detect marker growth, but only as a marker that found in lung cancer. But Interleukin-6 (IL-6) as the one of the pro-inflammation cytokines that shows an increased in patients Non-Small Cell Lung Cancer (NSCLC).